Unlock Full Company Report

Access verified contacts, investors & buying signals.

Get Access
Recently Funded|Amount: USD 100.0M|Industry: Biotechnology Research

MEI Pharma Secures $100 Million in Funding to Accelerate Next-Generation Cancer Therapies

MEI Pharma

MEI Pharma Logo
N/A
51-200 employees employees (Est.)
Visit Website
View Full Report

Includes contacts, investors & buying signals

MEI Pharma is excited to announce the successful closing of a $100 million funding round, a monumental milestone that accelerates our mission to transform cancer treatment through innovative and best-in-class therapies. As a San Diego-based clinical-stage pharmaceutical company, we are dedicated to developing novel cancer treatments that offer improved outcomes for patients battling hematological malignancies and solid tumors. This significant capital infusion will be strategically deployed to advance our robust pipeline, which includes promising candidates such as Zandelisib, voruciclib, and ME-344. Zandelisib, formerly known as ME-401, is currently undergoing multiple clinical trials targeting B-cell malignancies, with the goal of securing marketing approvals from the FDA and other global regulatory agencies. Meanwhile, our potent CDK9 inhibitor voruciclib is being explored for use in combination therapies, aiming to enhance the treatment landscape for various cancers. Additionally, ME-344, a mitochondrial inhibitor, is poised to make an impact in treating solid tumors. The new funding will not only bolster our clinical development efforts but also support our ongoing research to optimize the balance between drug efficacy and tolerability, ensuring that patient needs remain at the forefront of our endeavors. At MEI Pharma, we hold ourselves to the highest standards of dedication, mutual trust, personal accountability, and fiscal discipline as we progress toward our mission. This milestone reaffirms our commitment to innovation in oncology treatment, paving the way for enhanced therapies and brighter futures for patients worldwide. Interested readers and potential collaborators are invited to explore career opportunities with our team by visiting meipharma.com/careers.
July 18, 2025

Buying Signals & Intent

Our AI suggests MEI Pharma may be interested in solutions related to:

  • Clinical Research
  • Drug Development
  • Investor Relations
  • Healthcare Investment
  • Biotech Collaborations

Sell these products?

Unlock full report to find contacts.

Get Access Now

Investors

Unlock Investor Data

See who invested in MEI Pharma and potentially find related investment contacts.

Unlock Premium Access

Key Decision Makers

Unlock Verified Contacts

Get direct email addresses and phone numbers for key decision makers at MEI Pharma.

Unlock Contacts Now